- Home
- Investing
- Mutual Funds
Outsize exposure to an outperforming tech stock and a pair of drugmakers have boosted recent returns for the Primecap Odyssey Growth Fund.
By
Nellie S. Huang
published
28 February 2026
in Features
When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works.
- Copy link
- X
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.
Contact me with news and offers from other Future brands Receive email from us on behalf of our trusted partners or sponsors By submitting your information you agree to the Terms & Conditions and Privacy Policy and are aged 16 or over.You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
Delivered daily
Kiplinger Today
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more delivered daily. Smart money moves start here.
Signup +
Sent five days a week
Kiplinger A Step Ahead
Get practical help to make better financial decisions in your everyday life, from spending to savings on top deals.
Signup +
Delivered daily
Kiplinger Closing Bell
Get today's biggest financial and investing headlines delivered to your inbox every day the U.S. stock market is open.
Signup +
Sent twice a week
Kiplinger Adviser Intel
Financial pros across the country share best practices and fresh tactics to preserve and grow your wealth.
Signup +
Delivered weekly
Kiplinger Tax Tips
Trim your federal and state tax bills with practical tax-planning and tax-cutting strategies.
Signup +
Sent twice a week
Kiplinger Retirement Tips
Your twice-a-week guide to planning and enjoying a financially secure and richly rewarding retirement
Signup +
Sent bimonthly.
Kiplinger Adviser Angle
Insights for advisers, wealth managers and other financial professionals.
Signup +
Sent twice a week
Kiplinger Investing Weekly
Your twice-a-week roundup of promising stocks, funds, companies and industries you should consider, ones you should avoid, and why.
Signup +
Sent weekly for six weeks
Kiplinger Invest for Retirement
Your step-by-step six-part series on how to invest for retirement, from devising a successful strategy to exactly which investments to choose.
Signup + An account already exists for this email address, please log in. Subscribe to our newsletter
After two lackluster years, the Primecap Odyssey Growth Fund (POGRX) is back. In 2025, the fund gained 33%, beating the S&P 500 Index, which climbed 18%, as well as 99% of all large-company stock funds.
Moreover, the fund did so without a big allocation to communications services and information technology companies, which top the performance charts and dominate the broad market.
Combined, the communications services and information technology sectors account for nearly half of the S&P 500 (they advanced 34% and 24%, respectively, over the past 12 months). But those sectors make up just over one-third of the Primecap portfolio.
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
CLICK FOR FREE ISSUE
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Sign upInstead, POGRX, which is a member of the Kiplinger 25, our favorite no-load mutual funds, has hefty exposure to health care (26% of the fund's assets) and industrial stocks (18%). Health shares struggled for much of 2025 but rallied to finish with a 15% gain. And industrials returned 19%, just ahead of the broad market.
The fund's outperformance boils down to good stock picking, not sector exposures. Its best performers in 2025 included tech stocks, of course, such as Micron Technology (MU), which soared 240%.
But a few drug companies — BeOne Medicines (ONC), up 64%, and Rhythm Pharmaceuticals (RYTM), up 91%, for example — and a consumer-sector stock, Chinese e-commerce behemoth Alibaba Group Holding (BABA), up 75%, pepper the top contributors, too.
Primecap Odyssey Growth managers go their own way
Five managers divide the assets at Odyssey Growth and run their portion independently. But they all focus on growing companies priced at a discount with a catalyst to drive prices higher.
The process tends to create a portfolio that bears little resemblance to the S&P 500. For example, instead of the usual mega-size tech names, the fund's top holdings are pharma giant Eli Lilly (LLY); Xometry (XMTR), a Maryland–based machinery maker; and the aforementioned BeOne Medicines.
Over the past decade, the fund's 14.1% annualized return beat 65% of large-cap stock funds but lagged the 14.8% record of the S&P 500.
Note: This item first appeared in Kiplinger Personal Finance Magazine, a monthly, trustworthy source of advice and guidance. Subscribe to help you make more money and keep more of the money you make here.
Related Content
- Best Mutual Funds to Invest In for 2026
- Why Invest In Mutual Funds When ETFs Exist?
- Kiplinger's Mutual Fund Guide For 2025
Nellie S. HuangSocial Links NavigationSenior Editor, Kiplinger Personal Finance MagazineNellie joined Kiplinger in August 2011 after a seven-year stint in Hong Kong. There, she worked for the Wall Street Journal Asia, where as lifestyle editor, she launched and edited Scene Asia, an online guide to food, wine, entertainment and the arts in Asia. Prior to that, she was an editor at Weekend Journal, the Friday lifestyle section of the Wall Street Journal Asia. Kiplinger isn't Nellie's first foray into personal finance: She has also worked at SmartMoney (rising from fact-checker to senior writer), and she was a senior editor at Money.
Latest-
5 Laundry Habits That Are Costing You Money
You might be flushing money down the drain if you have any of these laundry habits.
-
More Tools to Build a Bond Ladder
Vanguard aims to launch a line of target-maturity corporate bond ETFs.
-
Why Your Pet Should Be In Your Estate Plan — Yes, Really
Including your wishes in your will or in a pet trust can ensure proper care when you can’t provide it.
-
More Tools to Build a Bond Ladder
Vanguard aims to launch a line of target-maturity corporate bond ETFs.
-
A Newly Retired Couple With a Portfolio Full of Winners Faced a $50,000 Tax Bill: This Is the Strategy That Helped Save Them
Large unrealized capital gains can create a serious tax headache for retirees with a successful portfolio. A tax-aware long-short strategy can help.
-
5 Retirement Myths to Leave Behind (and How to Start Planning for the Reality)
Separating facts from fiction is an important first step toward building a retirement plan that's grounded in reality and not based on incorrect assumptions.
-
I'm a Financial Adviser: Silence Is Golden, But It Hurts Your Heirs More Than You Think
Talking to heirs about transferring wealth can be overwhelming, but avoiding it now can lead to conflict later. Here's how to start sharing your plans.
-
Dow Dives 521 Points as Goldman, AmEx Slide: Stock Market Today
News of Block's massive layoffs exacerbated AI worries across the financial sector.
-
The Merger Market is Heating Up. Here's How to Cash In
Investing in takeover deals can be a low-volatility way to diversify your portfolio.
-
Vanguard Cuts Fund Fees Again. Here's Why That's Important for You
Vanguard recently cut fees on dozens of ETFs and mutual funds, which is great news for investors. Here's why.
-
Ask the Editor, February 27: Questions on Tax Returns and Decedents
Ask the Editor In this week's Ask the Editor Q&A, Joy Taylor answers questions on how to file a tax return when someone has died and resources you can use to find more help.
